天圣制药被立案调查，股民索赔可期

Core Points - Tian Sheng Pharmaceutical Group Co., Ltd. (ST Tian Sheng) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1][2] - The company and its controlling shareholders may face civil compensation claims from investors who suffered losses due to alleged securities fraud [1][2] - A lawyer from Shanghai Hanlian Law Firm is collecting claims from affected investors, with specific conditions for eligibility outlined [2][3] Summary by Sections Company Investigation - Tian Sheng Pharmaceutical has been notified of a formal investigation by the CSRC due to suspected information disclosure violations [1] - The investigation could lead to civil liabilities for the company, its controlling shareholders, and related parties if investors' rights are found to be compromised [1] Investor Compensation - Affected investors who purchased Tian Sheng Pharmaceutical's securities before January 9, 2025, and sold or held them afterward may register for compensation claims [2] - The final conditions for claims will depend on the outcomes of the CSRC's administrative penalties and subsequent court rulings [2] Legal Process and Requirements - The progress of civil claims may be influenced by the company's potential delisting or bankruptcy proceedings [3] - Investors wishing to register for claims must provide specific documentation, including a copy of their ID and securities transaction records [3]